Samit Hirawat (Bristol Myers Squibb)
November 3, 2020 06:59 AM ESTUpdated 09:24 AM
R&D

Bris­tol My­ers wins a big bet as their PhI­II au­toim­mune drug beat out block­buster Ote­zla — and that could cost Am­gen dear­ly

John Carroll

Editor & Founder

Bris­tol My­ers Squibb $BMY bet big on a Phase III pso­ri­a­sis pro­gram for its TYK2 con­tender deu­cravac­i­tinib (BMS-986165). And to­day they’re de­clar­ing their heavy­weight con­tender …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times